GSK ‘well positioned' to cope with US pharmaceutical tariffs
A continued decline in vaccine sales at GSK in the first quarter was offset by growth in speciality medicines, and the drugs company said it was 'well positioned' to respond to any US pharmaceutical tariffs.
Total sales rose to £7.52 billion in the first three months of the year, up 4 per cent at constant currencies and ahead of City analyst forecasts of £7.42 billion.
Vaccine sales fell 6 per cent to £2.1 billion, with sales of its blockbuster shingles jab Shingrix and RSV vaccine Arexvy both weaker. However, similar to last year, speciality medicines sales rose 17 per cent to £2.9 billion, helped by oncology sales.
Core operating profit also rose by a better-than-expected 4 per cent to £2.5 billion in the first three
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Evening Standard
12 hours ago
- Evening Standard
UK stock markets rise with trading steady while US tariffs ‘in limbo'
The biggest risers on the FTSE 100 were M&G, up 12.3p to 236.7p, GSK, up 51p to 1,507p, BT, up 5.5p to 179.45p, AstraZeneca, up 322p to 10,720p, and Unite Group, up 21.5p to 861p.
Reuters
18 hours ago
- Reuters
Regeneron shares slide on mixed trial data on smoker's lung drug
May 30 (Reuters) - Regeneron (REGN.O), opens new tab shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi ( opens new tab were studying the potential blockbuster drug, itepekimab, as a treatment for chronic obstructive pulmonary disease (COPD) in adult former smokers. The condition has limited treatment options and the drug was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition. But after Friday's data, Barclays analyst Emily Field said Dupixent is likely to remain the first choice for doctors. GSK's (GSK.L), opens new tab Nucala, approved recently for COPD, is also a blockbuster drug. Nearly 16 million U.S. adults suffer from COPD, according to government data. Regeneron's shares, which have already fallen 15% this year, were trading at $530 in premarket trading. The company has a market capitalization of $65.36 billion. The company's itepekimab showed a significant reduction in exacerbations or flare-ups in the condition by 27% compared to placebo at 52 weeks in a 1,127-patient study. But the second study - which had enrolled fewer former smokers compared to the first - did not meet its goal although a benefit was seen earlier in the trial. The experimental drug, which is being jointly developed by Regeneron and Sanofi, binds to and inhibits interleukin-33, a type of protein that causes inflammation in COPD. COPD is a common lung disease causing restricted airflow and breathing problems. It typically affects smokers, but can also be caused by pollutants. Sanofi and Regeneron are assessing the data and will discuss with regulatory authorities to evaluate their next steps, the companies said. Regeneron's price to earnings ratio, a common benchmark for valuing stocks, was 16.15, compared with 13.62 for Gilead (GILD.O), opens new tab and 7.29 for Bristol Myers Squibb (BMY.N), opens new tab.
Reuters
3 days ago
- Reuters
GSK, Spero to stop urinary tract infection drug trial due to early success
May 28 (Reuters) - Spero Therapeutics (SPRO.O), opens new tab and partner GSK (GSK.L), opens new tab said on Wednesday an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the trial early for efficacy. Spero shares nearly tripled to $2 in premarket trading. The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial. The companies were studying the oral drug, tebipenem HBr, as a treatment for complicated urinary tract infections, including pyelonephritis, in which kidneys become infected. In the trial, the drug showed it was at least as good as an existing intravenous treatment in hospitalized adult patients. GSK plans to work with U.S. regulatory authorities to include the data as part of a filing in the second half of the year.
